Zobrazeno 1 - 10
of 429
pro vyhledávání: '"sodium‐glucose co‐transporter‐2 inhibitors"'
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-10 (2024)
Abstract Background Non-alcoholic fatty liver diseases (NAFLDs)/non-alcoholic steatohepatitis (NASH) are the most common liver disorders among patients with type 2 diabetes. Newer classes of glucose-lowering agents (GLAs), such as glucagon-like pepti
Externí odkaz:
https://doaj.org/article/30dd7f7150754683ae4a5cd14846afb7
Autor:
Cesare Berra, Roberto Manfrini, Francesco Bifari, Elisa Cipponeri, Renata Ghelardi, Lucia Centofanti, Umberto Mortola, Elena Lunati, Loredana Bucciarelli, Vincenzo Cimino, Franco Folli
Publikováno v:
Pharmacological Research, Vol 210, Iss , Pp 107517- (2024)
We evaluated the effects on glycemic control and body weight of a GLP1-RA in obese type 2 diabetic patients treated with SGLT2-inhibitors and other hypoglycemic agents and/or insulin, in a real-world setting. A cohort of 583 type 2 diabetic outpatien
Externí odkaz:
https://doaj.org/article/809d86e79ffb45e6b4dd60d82ba3bd1d
Publikováno v:
International Journal of General Medicine, Vol Volume 17, Pp 2613-2625 (2024)
Hua Liu,1,2,* Yang-Min Hao,1,2,* Sheng Jiang,1,2,* Maiheliya Baihetiyaer,1,2 Cheng Li,3 Guo-Yao Sang,4 Zhiming Li,5 Guo-Li Du1,2,6 1State Key Laboratory of Pathogenesis, Prevention, and Treatment of High Incidence Diseases in Central Asia
Externí odkaz:
https://doaj.org/article/fabcd40cf25845f8ba2f2864f96459d1
Autor:
Yan-Rong Li, Chih-Ching Wang, Chi-Hung Liu, Chieh-Li Yen, Victor Chien-Chia Wu, Evelyn Jou-Chen Huang, Ching-Yu Lee, Ching-Chung Hsiao
Publikováno v:
Frontiers in Endocrinology, Vol 15 (2024)
BackgroundSodium-glucose co-transporter-2 inhibitors (SGLT2i) have cardiovascular (CV) benefits, particularly in reducing the risk of heart failure (HF). Pioglitazone (Pio) has shown potential in decreasing the risks of recurrent stroke, non-fatal my
Externí odkaz:
https://doaj.org/article/9db77c0190d04830b8e27dc542f331ee
Publikováno v:
Kidney Medicine, Vol 6, Iss 8, Pp 100851- (2024)
Originally developed for use in type 2 diabetes mellitus (T2DM), sodium–glucose co-transporter-2 (SGLT2) inhibitors demonstrated diverse cardiovascular- and kidney-protective effects in large outcome trials. Their subsequent approval as a treatment
Externí odkaz:
https://doaj.org/article/e4a5f473d4f8447c86f52c8b6ba447b9
Publikováno v:
BMC Gastroenterology, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Introduction Evidence for dual antidiabetic therapy in type 2 diabetes mellitus patients with cirrhosis is limited. This study compared 5-year mortality, composite hepatic decompensation risk, and hepatocellular carcinoma occurrence in patie
Externí odkaz:
https://doaj.org/article/cb95011662544f27a4f7dd5eadb64fa6
Autor:
Shakta Mani Satyam, Laxminarayana Kurady Bairy, Abdul Rehman, Mohamed Farook, Sofiya Khan, Anuradha Asokan Nair, Nirmal Nachiketh Binu, Mohamed Yehya, Mohammed Moin Khan
Publikováno v:
Biology, Vol 13, Iss 9, p 672 (2024)
Recognizing the challenges posed by chemotherapy, specifically the hepatotoxic effects of drugs like cisplatin, this study aimed to examine the hepatoprotective potential of dapagliflozin to mitigate cisplatin-induced hepatotoxicity in a rat model. T
Externí odkaz:
https://doaj.org/article/0ac249886be34cc783419e28da92726c
Autor:
Jaehyun Lim, You-Jung Choi, Bong Sung Kim, Tae-Min Rhee, Hyun-Jung Lee, Kyung-Do Han, Jun-Bean Park, Jin Oh Na, Yong-Jin Kim, Heesun Lee, Hyung-Kwan Kim
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-10 (2023)
Abstract Background Sodium-glucose co-transporter-2 inhibitors displayed cardiovascular benefits in type 2 diabetes mellitus in previous studies; however, there were some heterogeneities regarding respective cardiovascular outcomes within the class.
Externí odkaz:
https://doaj.org/article/0d2af9992fa84eebac901391d3386036
Autor:
Nikki C. C. Werkman, Johanna H. M. Driessen, Coen D. A. Stehouwer, Peter Vestergaard, Nicolaas C. Schaper, Joop P. van den Bergh, Johannes T. H. Nielen
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-14 (2023)
Abstract Background Numerous studies have investigated the potential association of sodium-glucose co-transporter-2 inhibitors (SGLT2-Is) with an increased risk of lower limb amputations (LLAs), but have produced conflicting results. Particularly stu
Externí odkaz:
https://doaj.org/article/a3f95621d14c45b382e75bef4239e4b7
Autor:
Shakta Mani Satyam, Laxminarayana Kurady Bairy, Abdul Rehman, Mohamed Attia, Layth Ahmed, Karam Emad, Yusuf Jaafer, Abdelrehman Bahaaeldin
Publikováno v:
Biology, Vol 13, Iss 7, p 473 (2024)
This study was aimed to investigate the hepatoprotective potential of dapagliflozin and silymarin alone and in combination to combat carbon tetrachloride (CCl4)-induced hepatotoxicity and the anticipated mechanisms. Thirty female Wistar rats were ran
Externí odkaz:
https://doaj.org/article/8d56a962536d48bcbe4c5db1cea3c6a0